Literature DB >> 19489038

C/EBPbeta regulates metastatic gene expression and confers TNF-alpha resistance to prostate cancer cells.

Myoung H Kim1, Alena Z Minton, Vikas Agrawal.   

Abstract

BACKGROUND: CCAAT/enhancer-binding protein beta (C/EBPbeta) is a transcription factor and consists of three isoforms, transcription-activating A/B (C/EBPbeta-AB) and transcription inhibitory C (C/EBPbeta-C). We previously reported that C/EBPbeta-C was predominantly expressed in hormone-dependent LNCaP cells, while C/EBPbeta-AB forms were predominant in hormone-independent prostate cancer (HI-PCa) cells.
METHODS: Reporter gene analysis was performed to investigate transcriptional activity of C/EBPbeta on metastatic gene expression upon TNF-alpha treatment. NF-kappaB activation and C/EBPbeta protein upregulation were determined by immunoblotting. WST assay was used to determine the role of C/EBPbeta in TNF-alpha-induced cell death.
RESULTS: We first determined that the C/EBPbeta-C overexpression or siRNA-mediated C/EBPbeta depletion decreased TNF-alpha-induced promoter activities of Bfl-1, IL-6, and IL-8 genes. IL-6 and IL-8 are autocrine growth factors of HI-PCa cells and Bfl-1 is an anti-apoptotic protein whose function in prostate cancer is yet to be determined. Secondly, we determined differential regulation of C/EBPbeta by TNF-alpha. In DU-145 cells, C/EBPbeta was upregulated by TNF-alpha, but downregulated in LNCaP cells, although NF-kappaB was activated in both cells. This result suggested cell-type specific activation of signaling pathways leading to C/EBPbeta upregulation, which was distinct from that leading to NF-kappaB activation. Most importantly, C/EBPbeta depletion decreased cell growth and sensitized DU-145 cells to TNF-alpha-induced cell death. Conversely, overexpression of C/EBPbeta-A in LNCaP cells increased resistance to TNF-induced cell death and TNF-induced promoter activities of IL-6 and Bfl-1.
CONCLUSION: Our study, for the first time, demonstrated that C/EBPbeta regulated cell growth and conferred TNF-alpha resistance to PCa cells, in part, via regulation of metastatic gene expression. Prostate 69: 1435-1447, 2009. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19489038     DOI: 10.1002/pros.20993

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  17 in total

1.  C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction.

Authors:  Julia E Dooher; Ido Paz-Priel; Simone Houng; Albert S Baldwin; Alan D Friedman
Journal:  Mol Cancer Res       Date:  2011-08-03       Impact factor: 5.852

2.  Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti-inflammatory and Anti-cancer Activity, Disrupts the Cooperation of CCAAT Box/Enhancer-binding Protein β (C/EBPβ) and Co-activator p300.

Authors:  Anke Jakobs; Simone Steinmann; Sarah Marie Henrich; Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  J Biol Chem       Date:  2016-11-01       Impact factor: 5.157

Review 3.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

4.  Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells.

Authors:  Sichuan Xi; Maocheng Yang; Yongguang Tao; Hong Xu; Jigui Shan; Suzanne Inchauste; Mary Zhang; Leandro Mercedes; Julie A Hong; Mahadev Rao; David S Schrump
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

5.  Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner.

Authors:  Renate Louw-du Toit; Janet P Hapgood; Donita Africander
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

6.  Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD.

Authors:  Xiaotian Sun; Parvaneh Jefferson; Qing Zhou; James M Angelastro; Lloyd A Greene
Journal:  Mol Cancer Res       Date:  2019-11-01       Impact factor: 5.852

Review 7.  Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.

Authors:  Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  Molecules       Date:  2022-03-23       Impact factor: 4.411

8.  CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.

Authors:  D J Barakat; J Zhang; T Barberi; S R Denmeade; A D Friedman; I Paz-Priel
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

9.  C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.

Authors:  Maria V Yusenko; Amke Trentmann; Debora A Casolari; Luca Abdel Ghani; Mairin Lenz; Melanie Horn; Wolfgang Dörner; Stefan Klempnauer; Henning D Mootz; Maria Francisca Arteaga; Jan-Henrik Mikesch; Richard J D'Andrea; Thomas J Gonda; Carsten Müller-Tidow; Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  Oncogene       Date:  2021-05-06       Impact factor: 9.867

10.  MatrixCatch--a novel tool for the recognition of composite regulatory elements in promoters.

Authors:  Igor V Deyneko; Alexander E Kel; Olga V Kel-Margoulis; Elena V Deineko; Edgar Wingender; Siegfried Weiss
Journal:  BMC Bioinformatics       Date:  2013-08-08       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.